BIOCRYST PHARMACEUTICALS, INC. Debt Securities, Available-for-sale, Unrealized Loss Position
BIOCRYST PHARMACEUTICALS, INC. (BCRX) had Debt Securities, Available-for-sale, Unrealized Loss Position of $185.12 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Debt and Equity Securities
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition · last filed 2026-08-05
- 2026-06-30: Debt Securities, Available-for-sale, Unrealized Loss Position $185.12M.
- 2026-03-31: Debt Securities, Available-for-sale, Unrealized Loss Position $72.27M.
- 2025-12-31: Debt Securities, Available-for-sale, Unrealized Loss Position $20.30M.
- 2025-09-30: Debt Securities, Available-for-sale, Unrealized Loss Position $69.25M.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss Position |
|---|---|
| 2026-06-30 | $185.12M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $72.27M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $20.30M 10-K · filed 2026-02-26 |
| 2025-09-30 | $69.25M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $59.12M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $19.74M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $44.10M 10-K · filed 2025-02-25 |
| 2024-06-30 | $238.94M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $171.44M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $18.51M 10-K · filed 2024-02-27 |
| 2023-09-30 | $215.09K 10-Q · filed 2023-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |